After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that MacroGenics to Participate in Upcoming Investor Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Macrogenics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $10.91 and fluctuated between $11.18 as its day high and $10.42 as its day low. The current market capitalization of Macrogenics Inc is $676.75M. A total of 1.21 million shares were traded on the day, compared to an average of 673.57K shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, MGNX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 7 BUYs and 3 SELLs from insiders. Insiders purchased 1,033,125 shares during that period but sold 12,369.
In the most recent transaction, Bonvini Ezio sold 18,880 shares of MGNX for 10.08 per share on Dec 20. After the transaction, the Sr VP, Research & CSO now owns 101,300 company shares. In a previous transaction on Oct 02, BIOTECH TARGET N V bought 150,000 shares at 4.46 per share. MGNX shares that 10% Owner owns now total 9,929,963.
Among the insiders who bought shares, BIOTECH TARGET N V acquired of 200,000 shares on Sep 07 at a per-share price of $5.26. This resulted in the 10% Owner holding 9,779,963 shares of MGNX after the transaction. In another insider transaction, HURWITZ EDWARD bought 15,000 shares at $4.91 per share on Aug 30. Company shares held by the Director now total 33,074.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for MGNX in the last 3 months, the mean price target is $13.67 with high estimates of $20.00 and low estimates of $10.00. In terms of 52-week highs and lows, MGNX has a high of $10.99 and a low of $4.29.
As of this writing, MGNX has an earnings estimate of -$0.14 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of $0.38 per share and a lower estimate of -$0.37. The company reported an EPS of $0.92 in the last quarter, which was 276.90% higher than expectations of -$0.52.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MGNX’s latest balance sheet shows that the firm has $243.62M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $74.58M in liabilities at the time. Its Book Value Per Share was $3.13, while its Total Shareholder’s Equity was $239.62M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MGNX is Buy with a score of 4.64.
